VNDA Share Price Performance
US$6.84
2.01 (41.61%)
65.8% undervalued intrinsic discount
US$20.00
Fair Value
Price US$6.84
AnalystHighTarget US$20.00
AnalystConsensusTarget US$12.67
AnalystLowTarget US$5.00
Fair ValueUS$20.00
Share Pricen/a
Vanda Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
VNDA Community Narratives
AN
Fair Value US$20 65.8% undervalued intrinsic discount
Diversified Pipeline And Global Reach Will Advance Neurology Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$12.67 46.0% undervalued intrinsic discount
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
Fair Value US$5 36.8% overvalued intrinsic discount
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Diversified Pipeline And Global Reach Will Advance Neurology Markets
Key Takeaways Fanapt and Bysanti launches are set to deliver rapid, sustained revenue growth and significant margin improvement due to expanded prescriber engagement and high-margin patient transitions. Diversified late-stage pipeline and scalable commercial platform drive multi-year revenue resilience, with focus on specialty therapies providing durable margins and global market access.Read more
39
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$20
65.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
34.88% p.a.
Profit Margin
14.17%
Future PE
21x
Price in 2028
US$24.15
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
Key Takeaways Expansion of new product launches and increased sales efforts are driving strong growth in psychiatric and neurological treatment markets globally. Advancing a diverse pipeline in CNS and rare diseases reduces reliance on older products and supports long-term profitability through market exclusivity and improved margins.Read more
118
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
US$12.67
46.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
28.55% p.a.
Profit Margin
1.78%
Future PE
122.51x
Price in 2028
US$15.3
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
Key Takeaways Reliance on a narrow commercial base and high R&D costs create uncertainty for revenue growth, net margins, and operating leverage amid competitive and regulatory pressures. Expansion efforts and pipeline diversification face challenges from international pricing, reimbursement delays, and market volatility, potentially limiting returns from new launches and partnerships.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$5
36.8% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
27.82% p.a.
Profit Margin
16.25%
Future PE
5.38x
Price in 2028
US$6.04
Trending Discussion
Recently Updated Narratives
AN
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
Fair Value: US$5 36.8% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Diversified Pipeline And Global Reach Will Advance Neurology Markets
Fair Value: US$20 65.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
Fair Value: US$12.67 46.0% undervalued intrinsic discount
17 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vanda Pharmaceuticals Inc. Key Details
About VNDA
- Founded
- 2002
- Employees
- 368
- CEO
- WebsiteView website
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company’s pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
